Company intelligence / Profile preview

Knight & Co

Ownership: Private
Employees: ~450
Development stage: Other

Overview

Knight Therapeutics operates a pan-American specialty pharmaceutical business focused on acquiring/inlicensing innovative late-stage/commercialized drugs for Canada and Latin America. Recent deals include exclusive Canadian rights to MYFEMBREE®, ORGOVYX®, vibegron, IMVEXXY®, BIJUVA®, TRELSTAR®, among others. The company generated C$11.2 million revenue from these new assets in fiscal year ending March 2025. Its strategy emphasizes risk mitigation by focusing on late-stage/commercial assets rather than early R&D programs; it also invests in branded generics for stable earnings in Latin America.

Therapeutic areas: OncologyUrologyWomen's Health
Modalities: Small moleculeBiologicHormone
Industry: Biotech

Partnerships

Sumitomo Pharma/Sumitomo Pharma America Inc.Forbion Capital Partners

Beyond the preview

Go deeper on Knight & Co.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Knight & Co.

Explore the full profile